US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Register with your email to read the full article.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
More in NEWLY PUBLISHED
NEWLY PUBLISHED
Top Companies Leading the Rare Disease Drug Discovery
KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...
NEWLY PUBLISHED
Liquid Biopsy: An Industrial Review
KEY POINTS The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent to reach over $3 ...
MARKET INSIGHTS
Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)
KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...
MARKET INSIGHTS
Billion Dollars Healthcare Startups (2018)
KEY POINTS A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has ...
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply